Although IDH-mutated glioma generally exhibit a better disease outcome (74), the incidence of IDH mutations in secondary tumour suggests that lower-grade glioma with IDH mutation often recur after having undergone malignant transformation to a higher grade. The gene discussed is IDH1; the disease is central nervous system cancer.